Neoplasms

All Conditions

Skin and Connective Tissue Diseases

Symptoms and General Pathology

Carcinoma

Breast Neoplasms

Neoplastic Cells, Circulating

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Breast Diseases

Skin Diseases

Neoplasm Metastasis

Neoplastic Processes

Central Nervous System Depressants

All Drugs and Chemicals

Platelet Aggregation Inhibitors

Anesthetics

Propofol

Sevoflurane

Hypnotics and Sedatives

Anesthetics, Intravenous

Anesthetics, General

Anesthetics, Inhalation

Beatrice Beck Schimmer, Prof MD

Serious concern about the role of anesthesia in tumor recurrence has considerably risen over years, but the lack of surrogate markers for tumor spreading made trials addressing this issue difficult to realize. In breast cancer patients CTC positivity has been recently recognized as an independent prognostic factor. In this respect, we postulated that in a first step changes in the number of CTC after general anesthesia would help to determine the effect of anesthesia on this tumor marker.

Patients with primary breast cancer will be randomized to either propofol or sevoflurane anesthesia for curative surgery. CTC will be determined in the pre- as well as postoperative phase and the kinetic of CTC in the two groups will be compared.

Anesthesia and Circulating Tumor Cells in Breast Cancer

Does Anesthesia Technique Affect the Presence of Circulating Tumor Cells in Primary Breast Carcinoma? A Randomised Controlled Trial.

University of Zurich

Jonnathan Guadalupe Santillán Benítez, MSc

Leobardo Manuel Gómez Oliván, PhD

Hugo Mendieta Zeron, PhD

Objective:

Evaluate body mass index (BMI), leptin, Leptin/adiponectin (L/A) ratio and cancer antigen (CA) 15-3 together as reliable biomarkers for breast cancer.

Patients:

Consecutive patients aged between 40 - 60 years, with breast disease and informed consent.

Interventions:

Patients' Anthropometric and laboratorial characteristics classified by BMI in the group of cancer and patients with benign breast disease as well as biochemical tests of leptin, adiponectin,CA 15-3, hemoglobin, glucose low-density lipoprotein cholesterol (LDLC), high-density lipoprotein cholesterol (HDLC) levels were obtained as well as a blood sample to analyze CA 15-3 levels with a electrochemiluminescence immunoassay.

Hypothesis:

Using together leptin, L/A ratio, CA 15-3 and BMI could offer a reliable approach to detect high risk women to develop breast cancer.

Serum levels of leptin, adiponectin and CA 15-3, as well as anthropometric and biochemical parameters were analyzed in 88 female patients attending mammography study. Predictive values of BMI, leptin, L/A ratio and CA 15-3 were determined with 95% confidence interval (CI).

The Tetrad BMI, Leptin, Leptin/Adiponectin (L/A) Ratio and CA-15-3 is a Reliable Biomarker of Breast Cancer

Phase 1. Collect Samples of Breast Biopsy Patients Treated at the Hospital Radiology Service Maternal Perinatal Monica Pretelini

Universidad Autonoma del Estado de Mexico

Materno-Perinatal Hospital of the State of Mexico

Patients receive 1-2 text messages a few weeks before and 1 text message 24 hours before their mammography screening appointment. Patients also receive a phone call reminder as per standard practice.

Questionnaire Administration

Telephone-Based Intervention

Nestor Esnaola

This pilot clinical trial studies how well technology and health communication works in improving health outcomes in patients scheduled for mammography screening. The Mobile Mammography Screening Program provides a vital health service and it is important that all women scheduled for an appointment show-up to be screened. Technology and health communication may help decrease no-show rates among patients scheduled for mammography screening.

PRIMARY OBJECTIVES:

I. To decrease the mobile mammography unit no-show rate by sending text message appointment reminders to patients.

II. To assess the efficacy of the text message reminders at addressing the no-show rate by collecting satisfaction survey data from patients that received the texts and that came to their scheduled appointment.

OUTLINE:

Patients receive 1-2 text messages a few weeks before and 1 text message 24 hours before their mammography screening appointment. Patients also receive a phone call reminder as per standard practice.

Technology and Health Communication in Improving Health Outcomes in Patients Scheduled for Mammography

Text for Health: Integrating Technology and Health Communication to Improve Health Outcomes (Part 2 of 2)

The change (or lack of change) in the corporate sites? no-show rate will be compared to the change (or lack of change) in the community sites? no-show rate. Descriptive statistics will be used to describe the results.

Descriptive statistics will be used to report the results of the satisfaction survey.

National Cancer Institute (NCI)

Fox Chase Cancer Center

Carcinoma, Ductal

Carcinoma in Situ

Carcinoma, Intraductal, Noninfiltrating

Adenocarcinoma

Breast Carcinoma In Situ

Antineoplastic Agents

Fulvestrant

Antineoplastic Agents, Hormonal

Estrogens

Estrogen Antagonists

Estrogen Receptor Antagonists

Hormones

Hormone Antagonists

500mg fulvestrant administered intramuscularly

up to 500mg fulvestrant administered intraductally

Steven C Quay

This is an open-label, non-randomized pharmacokinetic study of fulvestrant in women scheduled for mastectomy or lumpectomy. Eligible subjects will be identified with breast cancer or DCIS. The first subject of each of five groups will receive fulvestrant intramuscularly. The subsequent 5 subjects of each group will receive fulvestrant by intraductal instillation. All subjects will be monitored for systemic and local adverse events during the procedure, and following the procedure until mastectomy or lumpectomy. Subjects that receive fulvestrant will undergo serial blood draws to determine fulvestrant blood concentration levels.

This is an open-label, non-randomized pharmacokinetic study of pre-surgical fulvestrant in women scheduled for mastectomy or lumpectomy. Eligible subjects will be identified upon admission to the institution for surgical management of breast cancer or DCIS, specifically mastectomy or lumpectomy. There will be 5 groups, each consisting of 6 subjects. The first subject of each group will receive fulvestrant administered intramuscularly and the next 5 subjects will receive fulvestrant intraductally. Subjects where at least 1 suitable duct is identified may undergo nipple aspiration in order to facilitate duct identification and intraductal infusion of a fulvestrant accompanied by imaging (saline+ ultrasound). A maximum of 5 ducts will receive intraductal infusion of fulvestrant. Across all ducts, the total dose will not exceed 500 mg (10 mL). All subjects will be monitored for systemic and local adverse events during the procedure, immediately following the procedure, within 30 minutes, 1 hour, 4 hours and by phone following discharge on Days +1 and +2, +7, and pre-operative. Subsequent to mastectomy or lumpectomy, subjects will be assessed for systemic adverse events until discharge. Subjects that receive fulvestrant will undergo serial blood draws to determine fulvestrant blood concentration levels.

This study was terminated due to revised commercial analyses including a review of the potential to enroll in a timely manner the planned number of patients. This study was not terminated because of safety or efficacy concerns.

A Pre-Surgical PK Study of IM and Intraductally Delivered Fulvestrant

An Open Label, Phase 2 Pharmacokinetic Study of Pre-Surgical Intramuscular and Intraductal Fulvestrant in Women With Invasive Breast Cancer or DCIS Undergoing Mastectomy or Lumpectomy

Number of adverse events per CTCAE v4.0 after treatment with fulvestrant by route of administration

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Anesthesia and Circulating Tumor Cells in Breast Cancer	NCT02005770	Female Breast C...	Sevoflurane Propofol	18 Years - 85 Years	University of Zurich
The Tetrad BMI, Leptin, Leptin/Adiponectin (L/A) Ratio and CA-15-3 is a Reliable Biomarker of Breast Cancer	NCT01643148	Female Breast C...		40 Years - 60 Years	Materno-Perinatal Hospital of the State of Mexico
Technology and Health Communication in Improving Health Outcomes in Patients Scheduled for Mammography	NCT04290585	Female Breast C... Healthy Subject	Questionnaire A... Telephone-Based...	-	Fox Chase Cancer Center
A Pre-Surgical PK Study of IM and Intraductally Delivered Fulvestrant	NCT02540330	Female Breast C... Female Ductal C...	Fulvestrant	18 Years -	Atossa Therapeutics, Inc.
A Pre-Surgical PK Study of IM and Intraductally Delivered Fulvestrant	NCT02540330	Female Breast C... Female Ductal C...	Fulvestrant	18 Years -	Atossa Therapeutics, Inc.

Spots Global Cancer Trial Database for female breast carcinoma